Restless Leg Syndrome: Causes, Symptoms, and Treatment

What Is Restless Leg Syndrome?

Restless leg syndrome (RLS), also called Willis-Ekbom disease, is a neurological sensorimotor disorder causing an overwhelming urge to move the legs at rest. The sensation is typically described as crawling, tingling, burning, or aching — almost always relieved by movement, and worst in the evening or at night.

RLS affects an estimated 5–10% of adults in Western populations. It is more prevalent in women and increases in frequency with age. It is one of the most underdiagnosed neurological disorders because symptoms are often attributed to anxiety, vascular problems, or plain restlessness.

The Four Diagnostic Criteria (IRLSSG)

The International Restless Legs Syndrome Study Group requires all four of the following for a clinical diagnosis:

• Urge to move the legs, usually accompanied by uncomfortable sensations
• Symptoms begin or worsen at rest (sitting or lying down)
• Partial or complete relief with movement (walking, stretching)
• Worse in the evening or at night compared to daytime

A fifth criterion — symptoms not explained by another condition — is applied to rule out mimics such as peripheral neuropathy, venous insufficiency, or leg cramps.

Causes and Pathophysiology

Dopamine Dysregulation

The leading neurological hypothesis centers on impaired dopaminergic transmission in the basal ganglia and spinal cord. Dopamine modulates sensorimotor integration; reduced activity in the A11 diencephalospinal dopamine pathway is consistently associated with RLS symptoms. This explains why dopamine agonists are effective first-line treatments.

Iron Deficiency

Iron is a required cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. Multiple studies show that serum ferritin below 75 mcg/L correlates with RLS severity, even when hemoglobin is normal. Brain iron deficiency appears independent of systemic iron stores in some patients.

Genetic Factors

Genome-wide association studies have identified risk variants in BTBD9, MEIS1, MAP2K5, and PTPRD. First-degree relatives of RLS patients have a 3–5 times higher risk of developing the condition. Genetic RLS typically presents before age 45 and progresses more slowly.

Secondary Causes

• Pregnancy: RLS affects 20–25% of pregnant women, particularly in the third trimester, often resolving postpartum.
• Chronic kidney disease: Up to 30% of dialysis patients have RLS, likely due to uremic toxins and iron/folate deficiency.
• Medications: Antidopaminergic drugs (antipsychotics, metoclopramide), certain antihistamines, and some antidepressants can trigger or worsen RLS.
• Neuropathy: Peripheral nerve damage from diabetes or other causes can produce RLS-like symptoms.

RLS vs. Periodic Limb Movement Disorder

RLS is a waking sensory disorder. Periodic limb movement disorder (PLMD) involves repetitive involuntary leg jerks during sleep, occurring every 20–40 seconds. About 80% of RLS patients also have PLMD, but PLMD can occur without RLS. PLMD requires polysomnography for diagnosis.

Diagnosis Process

After clinical assessment using the four IRLSSG criteria, a physician will typically order:

• Serum ferritin and transferrin saturation (target ferritin >75 mcg/L)
• Complete blood count, metabolic panel, renal function
• Thyroid function tests
• Vitamin B12 and folate

Polysomnography is not required for RLS diagnosis but is ordered when PLMD is suspected or to assess overall sleep quality.

Treatment Options

Non-Pharmacological Approaches

For mild to moderate RLS, behavioral and lifestyle changes can provide meaningful relief. Sleep hygiene improvements that target consistent sleep and wake times reduce circadian exacerbation of symptoms.

• Regular moderate aerobic exercise (not vigorous evening workouts)
• Leg massages and warm baths before bed
• Mental engagement activities during periods of forced rest
• Reducing or eliminating caffeine and alcohol
• Reviewing medications with your physician for RLS-triggering agents

Iron Supplementation

When ferritin is below 75 mcg/L, oral iron supplementation (ferrous sulfate 325 mg) is the first therapeutic step. For patients with poor oral absorption, intravenous iron (ferric carboxymaltose) has shown significant symptom reduction in clinical trials.

Dopamine Agonists

Pramipexole (0.125–0.5 mg nightly) and ropinirole (0.25–4 mg nightly) are FDA-approved for moderate-to-severe RLS. They are highly effective but carry a risk of augmentation — a paradoxical worsening where symptoms spread earlier in the day and increase in intensity with long-term use.

Alpha-2-Delta Ligands

Gabapentin enacarbil (Horizant, 600 mg nightly) is FDA-approved and is increasingly preferred over dopamine agonists due to lower augmentation risk. Pregabalin is used off-label with similar efficacy. These agents are particularly effective when RLS coexists with pain or anxiety.

Opioids

Low-dose opioids (oxycodone, methadone, buprenorphine) are reserved for refractory severe RLS unresponsive to other treatments, given dependency and side-effect profiles.

Sleep Environment and Mattress Considerations

Because RLS worsens when lying still, your mattress choice and sleep position have a direct impact on symptom severity and sleep quality. Key considerations:

• Firmness: A medium to medium-firm mattress reduces the need to shift positions constantly, supporting muscles and minimizing pressure-point discomfort.
• Temperature: Overheating exacerbates RLS. A cooling mattress with airflow-optimized layers can reduce symptom triggers.
• Side sleeping with knee support: A pillow between the knees reduces leg pressure and can lower symptom frequency.

For people with RLS and comorbid back pain, a supportive hybrid mattress balances spinal alignment with pressure relief.

Living With RLS

RLS has a significant quality-of-life impact: studies show it causes an average of 1.5–3 hours of lost sleep per night in moderate-to-severe cases. Long-term sleep deprivation from RLS increases risk of depression, anxiety, cardiovascular disease, and metabolic dysfunction.

Patient advocacy organizations such as the RLS Foundation provide support groups, clinical trial registries, and updated treatment guidelines.

Frequently Asked Questions

What is the most common cause of restless leg syndrome?

Iron deficiency is the most commonly identified cause. Iron is required for dopamine synthesis in the substantia nigra. When serum ferritin falls below 75 mcg/L, RLS symptoms typically worsen. Other causes include kidney disease, pregnancy, and genetic variants.

How is restless leg syndrome diagnosed?

Diagnosis is clinical, based on four IRLSSG criteria: an urge to move the legs, worsening at rest, relief with movement, and worse symptoms in the evening or at night. There is no definitive blood test or imaging scan.

What medications are used for RLS?

First-line pharmacotherapy includes dopamine agonists (pramipexole, ropinirole), alpha-2-delta calcium channel ligands (gabapentin enacarbil, pregabalin), and low-dose opioids for refractory cases. Iron supplementation is recommended when ferritin is below 75 mcg/L.

Can sleeping position affect RLS symptoms?

Many patients report that lying on their side with a pillow between the knees reduces the sensation of pressure and improves comfort. A supportive mattress that maintains spinal alignment reduces muscle tension, which can lower RLS trigger frequency.

Is RLS a lifelong condition?

Primary (idiopathic) RLS is typically chronic but fluctuating. Secondary RLS linked to iron deficiency, pregnancy, or medications may resolve once the underlying cause is treated. Severity often increases with age in primary cases.